| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2019: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
Although various driver mutations have been identified and molecular targeted therapies are being developed in lung adenocarcinoma (LAD), many cases lack these driver mutations and drug-resistance is easily acquired based on the temporal and spatial heterogeneity of cancers. In this study, we focused on the founder epi-driver type tumor suppressor genes (TSGs), which shows frequent tumor-specific hypermethylation from early stage, as a diagnostic and therapeutic target molecule that can overcome these issues. As a result, we have developed epi-markers that can be detected in plasma to detect early stage LAC or recurrence and predict therapeutic efficacy. We also identified therapeutic target epi-driver TSGs and related molecular pathways, and selected chemical compounds that mimic the activation of these pathways by through in silico screening.
|
